Clomipramine: Difference between revisions

From Glioblastoma Treatments
Jump to navigationJump to search
VisualWikitext
No edit summary
No edit summary
Line 1: Line 1:
{{TreatmentInfo
{{TreatmentInfo
|drug_name=Clomipramine
|drug_name=Clomipramine (Chlorimipramine)
|FDA_approval=Yes
|FDA_approval=Yes (for depression and obsessive-compulsive neuroses)
|used_for=Depression, Obsessive-compulsive disorder, GBM
|used_for=High-grade gliomas, including glioblastoma multiforme (GBM)
|clinical_trial_phase=Initial findings reported; further research needed
|common_side_effects=Known for its general tolerability; specific studies on glioma treatment might reveal more details
|OS_without=Median survival with traditional treatments like BCNU alone reported at 11 months
|OS_with=When combined with chloroquine, median survival extended to 25-33 months according to early studies
|PFS_without=Not specified
|PFS_with=Improvement in PFS-6 when combined with traditional chemotherapy agents
|usefulness_rating=3
|notes=Clomipramine, an antidepressant, has shown promise in treating high-grade gliomas by selectively depressing mitochondrial function in glioma cells, leading to apoptosis. Initial studies suggest potential efficacy in extending survival when combined with chemotherapy, though further detailed research is essential to validate these findings and explore mechanisms like autophagy inhibition.
|category=Repurposed Drugs
|category=Repurposed Drugs
|notes=This old FDA-approved drug was first used for the treatment of depression, and now also
|links=
for treatment of obsessive-compulsive neuroses. Its rationale as a treatment for gliomas is
that it selectively depresses mitochondrial function in glioma cells while leaving normal
cells unaffected, causing the glioma cells to undergo apoptosis (programmed cell death).
Reported at the 2005 ASCO meeting (122) was a clinical trial evaluating the outcome of
its use with 27 patients with high-grade gliomas (the distribution of GBMs vs. grade 3
tumors was not reported in the abstract, nor was the clinical history of the patients).
Chlorimipramine was added to their conventional treatment with doses from 25 mg daily
escalated to 150 mg daily. Median survival was 27 months; 20 of the 27 patients showed
partial tumor regressions. This appears to be a promising new treatment, although
additional testing with more detailed reporting of the results is clearly needed. An
interesting sidelight on chlorimipramine is that laboratory research has shown that it
strongly potentiates the toxicity of gleevec for glioma cells
}}
}}

Revision as of 09:27, 19 March 2024

Property Information
Drug Name Clomipramine (Chlorimipramine)
FDA Approval Yes (for depression and obsessive-compulsive neuroses)
Used for High-grade gliomas, including glioblastoma multiforme (GBM)
Clinical Trial Phase Initial findings reported; further research needed
Clinical Trial Explanation Not specified
Common Side Effects Known for its general tolerability; specific studies on glioma treatment might reveal more details
OS without Median survival with traditional treatments like BCNU alone reported at 11 months
OS with When combined with chloroquine, median survival extended to 25-33 months according to early studies
PFS without Not specified
PFS with Improvement in PFS-6 when combined with traditional chemotherapy agents
Usefulness Rating 3
Usefulness Explanation Not specified
Toxicity Level Not specified
Toxicity Explanation Not specified

Notes: Clomipramine, an antidepressant, has shown promise in treating high-grade gliomas by selectively depressing mitochondrial function in glioma cells, leading to apoptosis. Initial studies suggest potential efficacy in extending survival when combined with chemotherapy, though further detailed research is essential to validate these findings and explore mechanisms like autophagy inhibition.


From Ben Williams Book: Not specified

Loading comments...


Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=Clomipramine&oldid=55"